What is the therapeutic effect of Lenapavir Sodium/Salanka?

The therapeutic effect of Lenapavir Sodium/Sunlenca (Sunlenca) has been verified in multiple international clinical trials and real-world data, showing good efficacy and tolerability. As the world's first HIV (AIDS) capsid inhibitor, it interferes with the viral replication chain through multiple mechanisms, making it difficult for the virus to complete its normal life cycle in the body. Lenapavir sodium exhibits significant virological suppression in patients with persistent viral replication despite long-term multiple antiretroviral treatments.

In clinical practice, after patients receive lenapavir sodium treatment, their viral load can usually decrease significantly within weeks to months, and the efficacy can be further enhanced by combining it with other antiretroviral drugs. Its long-acting injection regimen has attracted particular attention. This half-yearly administration model not only maintains the stability of viral suppression, but also significantly improves patient compliance. ForHIV patients, long-term medication adherence is the key to successfully controlling the disease, and the low-frequency administration of Lenapavir sodium effectively reduces the risk of viral rebound caused by daily missed doses.

In terms of safety, lenapavir sodium is generally well tolerated. The most common adverse reactions are injection site reactions and mild gastrointestinal discomfort, which are tolerated by most patients. Compared with many traditional antiviral drugs, it does not show severe toxicity or cumulative side effects, which makes it an advantage in long-term treatment.

The efficacy of lenapavir sodium is not limited to virological indicators. It also brings new improvements tothe quality of life of HIV patients. During long-term treatment, patients can maintain stable condition with less drug intervention, which means less psychological pressure and life burden. Therefore, lenapavir sodium is not only an innovation in medicine, but also a change in the concept of HIV treatment. It allows antiviral drugs to move from "daily management" to the era of "long-term management".

Reference materials:https://www.drugs.com/sunlenca.html